Indegene revitalized sales for a global pharma company's mature RLS/Parkinson’s drug, targeting immunology and neurology patients amid declining prescriptions. With new pipeline drugs prompting salesforce reprioritization, challenges included stabilizing revenue and boosting market share. Indegene's software segmented HCPs by Rx potential and digital affinity to identify 1,065 whitespace targets, then orchestrated an omnichannel Rep Equivalence Model across integrated digital and virtual channels. This drove HCP engagement, reversed declines, and restored growth without traditional reps.

Join for free to read